<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INTRALIPIDÂ - soybean oilÂ emulsionÂ </strong><br>Baxter Healthcare CORP<br></p></div>
<h1>Intralipid<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="fbf6714d-5a82-42b0-b3b2-f5478ef10076"></a><a name="section-1"></a><p></p>
<p class="First">A 20% I.V. Fat Emulsion </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="d3816d82-90cc-4af0-adf1-5c0f35f9f1bd"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Intralipid<span class="Sup">Â®</span>Â 20% (A 20% Intravenous Fat Emulsion) is a sterile, non-pyrogenic fat emulsion prepared for intravenous administration as a source of calories and essential fatty acids. It is made up of 20% Soybean Oil, 1.2% Egg Yolk Phospholipids, 2.25% Glycerin, and Water for Injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8. pH range is 6 to 8.9.</p>
<p>The soybean oil is a refined natural product consisting of a mixture of neutral triglycerides of predominantly unsaturated fatty acids with the following structure:</p>
<p><img alt="fatacd" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-1-fatacid-intralp.jpg"></p>
<p>where <img alt="r1c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-2-r1c-intralip.jpg">,Â <img alt="r2c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-3-r2c-intralip.jpg"> andÂ <img alt="r3c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-4-r3c-intralp.jpg"> are saturated and unsaturated fatty acid residues.</p>
<p>The major component fatty acids are linoleic acid (44-62%), oleic acid (19-30%), palmitic acid (7-14%), Î±-linolenic acid (4-11%) and stearic acid (1.4-5.5%).<span class="Sup">1</span> Â These fatty acids have the following chemical and structural formulas:</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Linoleic acid<br>            C<span class="Sub">18</span>H<span class="Sub">32</span>O<span class="Sub">2</span>
</td>
<td class="Rrule" valign="top">
<img alt="lnacd" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-5-linacid-intralp.jpg"><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Oleic acid<br>            C<span class="Sub">18</span>H<span class="Sub">34</span>O<span class="Sub">2</span>
</td>
<td class="Rrule" valign="top">
<img alt="oldad" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-6-oleic-intrlp.jpg"><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Palmitic acid<br>            C<span class="Sub">16</span>H<span class="Sub">32</span>O<span class="Sub">2</span>
</td>
<td class="Rrule" valign="top">
<img alt="pamad" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-7-palacd-intralp.jpg"><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Î±-Linolenic acid<br>            C<span class="Sub">18</span>H<span class="Sub">30</span>O<span class="Sub">2</span><br>
</td>
<td class="Rrule" valign="top">
<img alt="linad" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-8-2nd-linacd-intrlp.jpg"><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Stearic acid<br>            C<span class="Sub">18</span>H<span class="Sub">36</span>O<span class="Sub">2</span>
</td>
<td class="Rrule" valign="top">
<img alt="strad" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-9-stear-intrlp.jpg"><br>
</td>
</tr>
</tbody></table>
<p>Purified egg phosphatides are a mixture of naturally occurring phospholipids which are isolated from the egg yolk. These phospholipids have the following general structure:</p>
<p><img alt="phph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-10-phph-intrlp.jpg"></p>
<br><p><img alt="r1c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-2-r1c-intralip.jpg">Â andÂ <img alt="r2c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-3-r2c-intralip.jpg"> contain saturated and unsaturated fatty acids that abound in neutral fats. R<span class="Sub">3</span> is primarily either the choline or ethanolamine ester of phosphoric acid.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<img alt="phscl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-11-phosclne-intrlp.jpg"><br>
</td>
<td class="Rrule" valign="top">
<img alt="phsam" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-12-phosamn-intrlp.jpg"><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Phosphatidylcholine</td>
<td class="Rrule" valign="top">Phosphatidylethanolamine</td>
</tr>
</tbody></table>
<p>Glycerin is chemically designated C<span class="Sub">3</span>H<span class="Sub">8</span>O<span class="Sub">3</span> and is a clear colorless, hygroscopic syrupy liquid. It has the following structural formula:</p>
<p><img alt="hyg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=intralipid-20-figure-13-hygsyp-intrlp.jpg"></p>
<p>Intralipid<span class="Sup">Â®</span> 20% (A 20% Intravenous Fat Emulsion) has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 350 mOsmol/kg water (which represents 260 mOsmol/L of emulsion) and contains emulsified fat particles of approximately 0.5 micron size.</p>
<p>The total caloric value, including fat, phospholipid and glycerin, is 2.0 kcal per mL of Intralipid<span class="Sup">Â®</span> 20%. The phospholipids present contribute 47 milligrams or approximately 1.5 mmol of phosphorus per 100 mL of the emulsion.</p>
<p>The primary plastic container (Biofineâ„¢), is made from multilayered film specifically designed for parenteral nutrition drug products. The film is polypropylene based comprising three co-extruded layers. It contains no plasticizers and exhibits virtually no leachables. The container does not contain DEHP (di(2-ethylhexyl)phthalate) or PVC. The container is nontoxic and biologically inert. This product is not made with natural rubber latex.</p>
<p>The container-emulsion unit is a closed system and is not dependent upon entry of external air during administration.</p>
<p>The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.</p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="beaefb91-c35a-4e42-8927-e3de3e84de84"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Intralipid<span class="Sup">Â®</span>Â 20% is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the clearing of chylomicrons.</p>
<p>Intralipid<span class="Sup">Â®</span>Â 20% will prevent the biochemical lesions of <span class="product-label-link" type="condition" conceptid="4029271" conceptname="Essential fatty acid deficiency">essential fatty acid deficiency</span> (EFAD), and correct the clinical manifestations of the EFAD syndrome.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="f1582c7e-5dee-4305-bf9c-ed6555fcaed6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Intralipid<span class="Sup">Â®</span>Â 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of EFAD.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="bba14ef8-0414-4ac4-9bb7-767f62c18082"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">The administration of Intralipid<span class="Sup">Â®</span>Â 20% is contraindicated in patients with disturbances of normal fat metabolism such as pathologic <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, lipoid <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> or <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> if accompanied by <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="c742cdff-5be7-4ffb-a74d-4fb47b8254eb"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="a067cfd3-1010-4ea9-88ad-7b4172bb38ae"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in preterm infants after infusion of intravenous fat emulsion have been reported in the medical literature.<span class="Sup">2</span> Autopsy findings included intravascular fat accumulation in the lungs. Treatment of premature and low birth weight infants with intravenous fat emulsion must be based upon careful benefit-risk assessment. Strict adherence to the recommended total daily dose is mandatory; hourly infusion rate should be as slow as possible in each case and should not in any case exceed 1Â g fat/kg in four hours. Premature and <span class="product-label-link" type="condition" conceptid="72726" conceptname="Light-for-dates with signs of fetal malnutrition">small for gestational age</span> infants have poor clearance of intravenous fat emulsion and increased free fatty acid plasma levels following fat emulsion infusion; therefore, serious consideration must be given to administration of less than the maximum recommended doses in these patients in order to decrease the likelihood of intravenous fat overload. The infantâ€™s ability to eliminate the infused fat from the circulation must be carefully monitored (such as serum triglycerides and/or plasma free fatty acid levels). The lipemia must clear between daily infusions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c2ae2f69-e643-4106-ace2-44c94e3170e7"></a><a name="section-6.1"></a><p></p>
<p class="First">Caution should be exercised in administering of Intralipid<span class="Sup">Â®</span>Â 20% (A 20% Intravenous Fat Emulsion) to patients with severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, pulmonary disease, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span>, or when there is danger of <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>.</p>
<p><span class="Bold">WARNING: </span>This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.</p>
<p>Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c7d7c609-d725-4156-8998-83483068e222"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">When Intralipid<span class="Sup">Â®</span>Â 20% is administered, the patients capacity to eliminate the infused fat from the circulation must be monitored by use of an appropriate laboratory determination of serum triglycerides. Overdosage must be avoided.</p>
<p>During long term intravenous nutrition with Intralipid<span class="Sup">Â®</span>Â 20%, liver function tests should be performed. If these tests indicate that liver function is impaired, the therapy should be withdrawn.</p>
<p>Frequent (some advise daily) platelet counts should be done in neonatal patients receiving parenteral nutrition with Intralipid<span class="Sup">Â®</span>Â 20%.</p>
<p>Drug product contains no more than 25 mcg/L of aluminum.</p>
<p><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></p>
<p>Studies with Intralipid<span class="Sup">Â®</span> have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.</p>
<p><span class="Bold">Pregnancy Category C:<span class="Italics">Â  </span></span>Animal reproduction studies have not been conducted with Intralipid<span class="Sup">Â®</span>. It is also not known whether Intralipid<span class="Sup">Â®</span> can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Intralipid<span class="Sup">Â®</span> should be given to a pregnant woman only if clearly needed.</p>
<p><span class="Bold">Nursing Mothers: </span>Caution should be exercised when Intralipid<span class="Sup">Â®</span> is administered to a nursing woman.</p>
<p><span class="Bold">Pediatric Use:<span class="Italics">Â  </span></span>See <a href="#c50d0223-2e40-4445-9de8-89c5e91bc2e4">DOSAGE AND ADMINISTRATION</a>.</p>
<p><span class="Bold">AVOID OVERDOSAGE ABSOLUTELY.</span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a4ad35d7-7bc8-4296-9dce-ed162adec798"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions observed can be separated into two classes:</p>
<ol class="Arabic">
<li>Those more frequently encountered are due: either to contamination of the intravenous catheter and result in <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, or to vein irritation by concurrently infused hypertonic solutions and may result in <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. These adverse reactions are inseparable from the hyperalimentation procedure with or without Intralipid<span class="Sup">Â®</span>Â 20% (A 20% I.V. Fat Emulsion).</li>
<li>Less frequent reactions more directly related to Intralipid<span class="Sup">Â®</span>Â 20% are: a) immediate or early adverse reactions, each of which has been reported to occur in clinical trials, in an incidence of less than 1%; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, hypercoagulability, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, increase in temperature, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest and back, slight pressure over the eyes, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and irritation at the site of infusion, and, rarely, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in neonates; b) delayed adverse reactions such as <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> due to central lobular <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, transient increases in liver function tests, and overloading syndrome (<span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">focal seizures</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>,    <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>).</li>
</ol>
<p>The deposition of a brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> in the reticuloendothelial system, the so-called â€œintravenous fat pigment,â€? has been reported in patients infused with Intralipid<span class="Sup">Â®</span>Â 20%. The causes and significance of this phenomenon are unknown.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="d326969e-2712-406b-bcc9-7f783c593d68"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of fat overload during therapy, stop the infusion of Intralipid<span class="Sup">Â®</span>Â 20% until visual inspection of the plasma, determination of triglyceride concentrations, or measurement of plasma light-scattering activity by nephelometry indicates the lipid has cleared. Re-evaluate the patient and institute appropriate corrective measures. See <a href="#c742cdff-5be7-4ffb-a74d-4fb47b8254eb">WARNINGS</a> and <a href="#c7d7c609-d725-4156-8998-83483068e222">PRECAUTIONS</a>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c50d0223-2e40-4445-9de8-89c5e91bc2e4"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Intralipid<span class="Sup">Â®</span> 20% should be administered as a part of Intravenous nutrition via peripheral vein or by central venous infusion.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="b5970205-102c-4039-a60e-fed740801842"></a><a name="section-10.1"></a><p></p>
<h2>Adult Patients</h2>
<p class="First">The initial rate of infusion in adults should be 0.5 mL/minute for the first 15 to 30 minutes of infusion. If no untoward reactions occur (see <a href="#a4ad35d7-7bc8-4296-9dce-ed162adec798">ADVERSE REACTIONS</a> section), the infusion rate can be increased to 1 mL/minute. Not more than 500 mL of Intralipid<span class="Sup">Â®</span>Â 20% should be infused into adults on the first day of therapy. If the patient has no untoward reactions, the dose can be increased on the following day. The daily dosage should not exceed 2.5Â g of fat/kg of body weight (12.5 mL of Intralipid<span class="Sup">Â®</span>Â 20% per kg). Intralipid<span class="Sup">Â®</span>Â 20% (A 20% I.V. Fat Emulsion) should make up no more than 60% of the total caloric input to the patient. Carbohydrate and a source of amino acids should comprise the remaining caloric input.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a042ad7e-0332-42bd-a7d8-91ff65faf9c8"></a><a name="section-10.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">The dosage for premature infants starts at 0.5Â g fat/kg body weight/24 hours (2.5 mL Intralipid<span class="Sup">Â®</span>Â 20%) and may be increased in relation to the infantâ€™s ability to eliminate fat. The maximum dosage recommended by the American Academy of Pediatrics is 3Â g fat/kg/24 hours.<span class="Sup">3</span></p>
<p>The initial rate of infusion in older pediatric patients should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL of Intralipid<span class="Sup">Â®</span>Â 20%/kg/hour. The daily dosage should not exceed 3Â g of fat/kg of body weight.<span class="Sup">3 </span>Â Intralipid<span class="Sup">Â®</span> 20% should make up no more than 60% of the total caloric input to the patient. Carbohydrate and a source of amino acids should comprise the remaining caloric input.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ee7110d7-a89f-40ce-9310-16a5c943e4fb"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4029271" conceptname="Essential fatty acid deficiency">Essential Fatty Acid Deficiency</span></h2>
<p class="First">When Intralipid<span class="Sup">Â®</span>Â 20% is administered to correct <span class="product-label-link" type="condition" conceptid="4029271" conceptname="Essential fatty acid deficiency">essential fatty acid deficiency</span>, eight to ten percent of the caloric input should be supplied by Intralipid<span class="Sup">Â®</span>Â 20% in order to provide adequate amounts of linoleic and linolenic acids. When EFAD occurs together with stress, the amount of Intralipid<span class="Sup">Â®</span>Â 20% needed to correct the deficiency may be increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c3a6b7a1-74a3-48f5-8514-f0da941f68cf"></a><a name="section-10.4"></a><p></p>
<h2>Administration</h2>
<p class="First">See <a href="#f69504bb-6044-4607-bb44-0f7a0fa9eb7c">MIXING GUIDELINES AND LIMITATIONS</a>Â section for information regarding mixing this fat emulsion with other parenteral fluids.</p>
<p>Intralipid<span class="Sup">Â®</span> 20% can be infused into the same central or peripheral vein as carbohydrate/amino acids solutions by means of a Y-connector near the infusion site. This allows for mixing of the emulsion immediately before entering the vein or for <span class="product-label-link" type="condition" conceptid="4311428" conceptname="Electrical alternation of heart">alternation</span> of each parenteral fluid. If infusion pumps are used, flow rates of each parenteral fluid should be controlled with a separate pump. Fat emulsion may also be infused through a separate peripheral site. Use a 1.2 micron filter with Intralipid<span class="Sup">Â®</span> 20%. Filters of less than 1.2 micron pore size must not be used. Conventional administration sets and TPN pooling bags contain polyvinyl chloride (PVC) components that have DEHP (di(2-ethylhexyl) phthalate) as a plasticizer. Fatâ€‘containing fluids such as Intralipid<span class="Sup">Â®</span> 20% extract DEHP from these PVC components and it may be advisable to consider infusion of Intralipid<span class="Sup">Â®</span> 20% through a non-DEHP administration set.</p>
<p>Do not use any bag in which there appears to be an oiling out on the surface of the emulsion.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="f69504bb-6044-4607-bb44-0f7a0fa9eb7c"></a><a name="section-10.5"></a><p></p>
<h2>MIXING GUIDELINES AND LIMITATIONS</h2>
<p class="First">Intralipid<span class="Sup">Â®</span> 20% (A 20% I.V. Fat Emulsion) may be mixed with Amino Acid and Dextrose Injections where compatibility have been demonstrated. Additives known to be incompatible should not be used. Please consult with pharmacist. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives (e.g., Vitamins and Minerals). </p>
<p>When being mixed the following proper mixing sequence must be followed to minimize pH related problems by ensuring that typically acidic Dextrose Injections are not mixed with lipid emulsions alone:</p>
<p>1. Transfer Dextrose Injection to the TPN Admixture Container</p>
<p>2. Transfer Amino Acid Injection</p>
<p>3. Transfer Intralipid<span class="Sup">Â®</span> 20% (A 20% Intravenous Fat Emulsion)</p>
<p>Note: Amino Acid Injection, Dextrose Injection and Intralipid<span class="Sup">Â®</span> 20% may be simultaneously transferred to the admixture container. Admixing should be accompanied by gentle <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> to avoid localized concentration effects.</p>
<br><p>Additives must not be added directly to Intralipid<span class="Sup">Â®</span> 20% and in no case should Intralipid<span class="Sup">Â®</span> 20% be added to the TPN container first. Bags should be shaken gently after each addition to minimize localized concentration.</p>
<p>If the admixture is not used immediately, the in-use storage time and conditions prior to use are the responsibility of the user and should normally not be longer than 24 hours at 2-8Â°C.</p>
<p>After removal from storage at 2-8Â°C, the admixture should be infused within 24 hours.</p>
<p>It is essential that the admixture be prepared using strict aseptic techniques as this nutrient mixture is a good growth medium for microorganisms.</p>
<p>Supplemental electrolytes, trace metals or multivitamins may be required in accordance with the prescription of the attending physician.</p>
<br><p>The prime destabilizers of emulsions are excessive acidity (low pH) and inappropriate electrolyte content. Careful consideration should be given to additions of divalent cations (Ca<span class="Sup">++</span> and Mg<span class="Sup">++</span>) which have been shown to cause emulsion instability. Amino acid solutions exert a buffering effect protecting the emulsion. The admixture should be inspected carefully for â€œbreaking or oiling outâ€œ of the emulsion. â€œBreaking or oiling outâ€? is described as the separation of the emulsion and can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion. The admixture should also be examined for particulates. The admixture must be discarded if any of the above is observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ac6f8b71-5a53-4381-a335-fb5f3618f30e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Intralipid<span class="Sup">Â®</span>Â 20% is supplied as a sterile emulsion in the following fill sizes: 100 mL, 250 mL and Â 500 mL. <br>100 mL:Â Â  0338-0519-58<br>250 mL:Â Â  0338-0519-09<br>500 mL:Â Â  0338 0519-13<br><br></p>
<p>Intralipid<span class="Sup">Â®</span> 20% is also available as Pharmacy Bulk Package in the following fill size. </p>
<p>1000 mL: 0338-0519-14</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="b3dbd993-bb55-44c1-9bc4-7df2a9f85bc3"></a><a name="section-12"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Intralipid<span class="Sup">Â®</span>Â 20% should not be stored above 25Â°C (77Â°F). Do not freeze Intralipid<span class="Sup">Â®</span>Â 20%. If accidentally frozen, discard the bag.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="c4f095ab-ac44-4e80-a3b0-eb00a3bd4714"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Padley FB: â€œMajor Vegetable Fats,â€? The Lipid Handbook (Gunstone FD, Harwood JL, Padley FB, eds.), Chapman and Hall Ltd., Cambridge, UK (1986), pp. 88-9.</li>
<li>Levene MI, Wigglesworth JS, Desai R: Pulmonary fat accumulation after Intralipid<span class="Sup">Â®</span> infusion in the preterm infant. Lancet 1980; 2(8199):815-8.</li>
<li>American Academy of Pediatrics: Use of intravenous fat emulsion in pediatric patients. Pediatrics 1981; 68:5(Nov) 738-43.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="afc5ba14-b198-4120-92e7-9b7a498ee517"></a><a name="section-14"></a><p></p>
<p class="First">(RevÂ May 2015)</p>
<p>Manufactured for<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Manufactured by<br><span class="Bold">Fresenius Kabi,</span><br>Uppsala, Sweden</p>
<p>Intralipid<span class="Sup">Â®</span> is a registered trademark of FreseniusÂ KabiÂ AB.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="f1f35fd2-2944-40ed-a2f2-d34a07e74169"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Instruction for Use - Intralipid<span class="Sup">Â®</span> 20% Container<br></span></p>
<br><div class="Figure"><img alt="figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=instruct-fig1.jpg"></div>
<br><div class="Figure"><img alt="figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=instruct-fig2.jpg"></div>
<br><div class="Figure"><img alt="figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=instruct-fig3.jpg"></div>
<br><div class="Figure"><img alt="figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=instruct-fig4.jpg"></div>
<br><div class="Figure"><img alt="figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=instruct-fig5.jpg"></div>
<br><div class="Figure"><img alt="figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=instruct-fig6.jpg"></div>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ee73115a-1045-4d57-a691-a373a9f2eec6"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Intralipid 250 mL Container Label</span></p>
<p><span class="Bold">NDC</span> 0338-0519-09</p>
<p><span class="Bold">Intralipid</span><span class="Sup">Â®</span>Â <span class="Bold">20%</span></p>
<p><span class="Bold">A 20% I.V. Fat Emulsion</span></p>
<p>250 mL <br>For Intravenous Use</p>
<p>Rx only</p>
<p>Â <img alt="bag 20" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69c82da-15ba-4d4d-8d7f-871dc3981eb8&amp;name=bag-20.jpg"></p>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTRALIPIDÂ 		
					</strong><br><span class="contentTableReg">soybean oil emulsion</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0519</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SOYBEAN OIL</strong> (SOYBEAN OIL) </td>
<td class="formItem">SOYBEAN OIL</td>
<td class="formItem">20Â g Â inÂ 100Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EGG PHOSPHOLIPIDS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0519-58</td>
<td class="formItem">100 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0338-0519-09</td>
<td class="formItem">250 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0338-0519-13</td>
<td class="formItem">500 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018449</td>
<td class="formItem">04/01/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Baxter Healthcare CORP
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Baxter Healthcare CORP (005083209)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi AB Uppsala</td>
<td class="formItem"></td>
<td class="formItem">559785113</td>
<td class="formItem">ANALYSIS(0338-0519), MANUFACTURE(0338-0519)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a69c82da-15ba-4d4d-8d7f-871dc3981eb8</div>
<div>Set id: a69c82da-15ba-4d4d-8d7f-871dc3981eb8</div>
<div>Version: 1</div>
<div>Effective Time: 20150616</div>
</div>
</div>Â <div class="DistributorName">Baxter Healthcare CORP</div></p>
</body></html>
